الفهرس 
OsteoporosisOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Glucocorticoids adminstration is the main cause of secondary osteoporosis. Although the exact mechanism of GIO is not completely understood, numerous findings suggested that GCs therapy-induced changes of bone meniral hemostasis, increase bone resorption, and decrease bone formation. Risedronate is a newly member of BPs and has anti-resorptive effect through a potent inhibitory action on osteoclasts and approved for the treatment and prevention of postmenopausal osteoporosis. Olmesratan is a selective ARBs and plays a key role in the regulation of arterial blood pressure, electrolyte balance, cardiovascular function, and has been reported to stimulate bone formation via its effect as anti-apoptotic agent of osteoytes and osteoblasts and decrease of bone resorption. The aim of that work was to investigate the possible prophylactic effects of olmesartan and risedronate separately and both of them on rat model of osteoporosis-induced by methylprednisolone acetate and the possible mechanism of action of both of them.